Clinical Trials Logo

Tumor Response Rate clinical trials

View clinical trials related to Tumor Response Rate.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03910140 Recruiting - Overall Survival Clinical Trials

TILA-TACE in Treatment of Hepatocellular Carcinoma

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate. However, as the study sample size was 40, the investigators need to validate the tumor response rate using a larger sample size; To validate the overall survival: in the previous study, the investigators showed that TILA-TACE significantly prolonged the overall survival of the patients with large and massive tumor. Again, the sample size was small, the investigators need to validate the data using a large sample size.